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Renal ischemia–reperfusion (IR) injury and cyclosporine A (CsA) nephrotoxicity affect
allograft function and survival. The prolonged effects and underlying mechanisms of
erythropoietin derived cyclic helix B peptide (CHBP) and/or caspase-3 small interfering
RNA (CASP-3siRNA) were investigated in mouse kidneys, as well as kidney epithelial
cells (TCMK-1), subjected to transplant-related injuries. Bilateral renal pedicles were
clamped for 30 min followed by reperfusion for 2 and 8 weeks, with/without 35 mg/kg
CsA gavage daily and/or 24 nmol/kg CHBP intraperitoneal injection every 3 days. The ratio
of urinary albumin to creatinine was raised by IR injury, further increased by CsA and
lowered by CHBP at 2, 4, 6 and 8 weeks, whereas the level of SCr was not significantly
affected. Similar change trends were revealed in tubulointerstitial damage and fibrosis,
HMGB1 and active CASP-3 protein. Increased apoptotic cells in IR kidneys were
decreased by CsA and CHBP at 2 and/or 8 weeks. p70 S6 kinase and mTOR
were reduced by CsA with/without CHBP at 2 weeks, so were S6 ribosomal protein
and GSK-3b at 8 weeks, with reduced CASP-3 at both time points. CASP-3 was further
decreased by CHBP in IR or IR + CsA kidneys at 2 or 8 weeks. Furthermore, in TCMK-1
cells CsA induced apoptosis was decreased by CHBP and/or CASP-3siRNA treatment.
Taken together, CHBP predominantly protects kidneys against IR injury at 2 weeks and/or
CsA nephrotoxicity at 8 weeks, with different underlying mechanisms. Urinary albumin/
creatinine is a good biomarker in monitoring the progression of transplant-related injuries.
CsA divergently affects apoptosis in kidneys and cultured kidney epithelial cells, in which
CHBP and/or CASP-3siRNA reduces inflammation and apoptosis.
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Kidney transplantation is the life-changing treatment for patients
with end-stage renal disease, whereas chronic allograft
dysfunction (CAD) and donor shortage are still major
obstacles (1). Ischemia–reperfusion (IR) injury, unavoidable in
organ transplantation, is associated with delayed graft function,
acute rejection, and subsequent CAD (2). IR injury initiates
immune responses, oxidative damage, inflammation and cell
death, in which tubular epithelial cells (TECs) are most
vulnerable (3–5). Survived TECs participate in alleviating
injury and promoting repair (6) via dedifferentiating and
entering cell cycle within a few hours post injury (7).
Cyclosporine A (CsA) as an immunosuppressant was used
after kidney transplantation to reduce acute rejection and early
graft losses (8). However, CsA has not improved long-term graft
survival due to its nephrotoxicity (9), characterized by
tubulointerstitial fibrosis and afferent arteriolar hyalinosis (10).
Erythropoietin (EPO) protected solid organs including
kidneys against IR injury through a heterodimer EPO receptor
and b-common receptor (EPOR/bcR), also named as innate
repair receptor. EPOR/bcR is pharmacologically distinct from
the homodimer receptor of (EPOR)2, a mediator of
erythropoiesis (11–13). We showed that EPO protected
kidneys against IR injury by decreasing tubular cell apoptosis,
but promoting inflammatory cell apoptosis (4, 14, 15). However,
the renoprotection of EPO required a large dosage that often
causes hypertension and thrombosis (16). Helix B surface
peptide (HBSP) was then developed from the 3D structure of
EPO, composed of 11 amino acids. HBSP only interacts with
EPOR/bcR, without stimulating (EPOR)2, but with a short serum
half-life only few minutes (17). A novel metabolic stable cyclic
HBSP (CHBP) was further produced by Chinese scientists, with
prolonged half-life and potent renoprotection (17–20).
Caspase-3 (CASP-3) is a crucial player in CAD, which executes
apoptosis and inflammation in transplant-related renal injuries (21,
22). In addition, HMGB1, a damage-associated molecule, is rapidly
released from nuclei to extracellular domains upon injury,
mediating apoptosis and inflammation (23), and subsequent
fibrosis (24, 25). Our previous study showed that CASP-3 and
HMGB1 were associated with the degree of renal IR injury and
fibrosis (22, 26), while CHBP and CASP-3 siRNA (CASP-3siRNA)
reduced CASP-3 and HMGB1 and improved renal injury (18, 22).
CHBP improved endoplasmic reticulum stress at 12 h, inhibited
inflammation and apoptosis at 5 and 7 days in mouse IR kidneys
(18, 26), and also effectively restored kidney function and structure
in isolated porcine IR kidneys and kidney grafts with acute rejection
(19, 27, 28). In addition, the continuous administration of HBSP
mitigated CASP-3, apoptosis, inflammation and fibrosis in 2-week
IR ± CsA kidneys, while CHBP administered at the onset of injury
reduced renal fibrosis after 12-week IR (19, 20). CHBP protected
aristolochic acid induced acute kidney injury and unilateral ureter
obstruction induced tubulointerstitial fibrosis (29, 30). CHBP also
ameliorated acute myocardial infarction and acute lung injury by
inhibiting apoptosis and inflammatory responses (31, 32).
Prolonged effects of CHBP and underling mechanisms are
worth exploring. In this study, therefore, the effect of CHBP onFrontiers in Immunology | www.frontiersin.org 2IR and/or CsA-induced combinational injuries in mouse kidneys
at 2 and 8 weeks (to avoid prolonged time increasing mortality)
and kidney epithelial cells, were further investigated. We
demonstrated that CHBP protected kidneys against transplant-
related injuries, which might be attributed to different
mechanistic signaling pathways at two time points, but both
with reduced CASP-3. CHBP and CsA may share comparable
immune regulations with the reduction of apoptosis in IR
kidneys, whereas CHBP and/or CASP-3siRNA protected
kidney epithelial cells against CsA-induced apoptosis.MATERIALS AND METHODS
Renal IR Injury Model
Male BALB/c mice 25–30 g were randomly divided into five groups:
Control, IR, IR + CsA, IR + CHBP, and IR + CsA + CHBP, with 5–8
mice in each group using power calculation according to the key
parameters of our previous studies (19–21). All animal procedures
were performed according to the guidelines from the Animal Care
and Use Committee of Nantong University and the Animal Care
Ethics Committee of Jiangsu Province. Mice were anesthetized by
1% pentobarbital (0.01 ml/g), and bilateral renal pedicles were
clamped for 30 min and reperfused for 2 or 8 weeks. The color
changing of kidneys was confirmed for the efficacy of occlusion and
reperfusion. For the sham control, abdominal cavity and renal
pedicels were exposed without occlusion. CsA (Novartis Pharma
GmbH, Eberbach, Germany) was dissolved in olive oil, gavage daily,
35 mg/kg body weight (BW). CHBP (Shanghai Institute of Materia
Medica, Chinese Academy of Sciences) was dissolved in 0.9% saline,
intraperitoneally injected after reperfusion every 3 days, 24 nmol/kg
BW (19, 27). Urine samples were collected every 2 weeks using
metabolic cages and used all 2-week urine samples including end
time point collection at 2 weeks end time points for analysis. At 2
and 8 weeks, the blood was drawn, animals were sacrificed and
harvested kidneys were fixed with 10% (w/v) neutral buffered
formalin or snap frozen in liquid nitrogen (Figure 1A). However,
not all mice survived to the end point, but at least n ≥3 were used for
the each group in all detections. Urinary albumin/creatinine and
serum creatinine (SCr) were measured using an automatic
biochemistry analyzer (Siemens, Berlin, Germany).
TCMK-1 Cell Model
TCMK-1 cells (a mouse kidney epithelial cell line, CCL139™,
American Type Culture Collection, Manassas, USA) (18) were
incubated in DMEM/F12 medium supplemented with 10% (v/v)
of fetal bovine serum (FBS, Gibco Technologies, Logan, USA),
100 unit/ml penicillin G (Gibco), and 100 mg/ml streptomycin
(Gibco) at 37°C in 5% CO2 atmosphere. The cells grown to about
80% confluent in monolayer in 6-well plates were treated by CsA
(2.5, 5, 10, 20 and 40 mg/ml) with/without CHBP (2.5, 5, 10, 20
and 40 ng/ml) for 24 h. TCMK-1 cells were transfected with
CASP-3siRNA (10, 20, 30 and 40 nM) by Lipofectamine@
RNAiMAX 4–6 h before above treatments (18, 26). The
sequences of CASP-3siRNA are: 5’-GCUUCUUCAGAGG
CGACUAtt-3’ and 5’-UAGUCGCCUCUGAAGAAGCta-3’,
with the negative control siRNA not targeting any knownJuly 2021 | Volume 12 | Article 697751
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Obtained data were from three independent experiments at
least (Figure 7A).
Histological Assessment
Approximately 4 µm paraffin sections were stained by hematoxylin
and eosin (H&E). The tubulointerstitial damage (TID) include
tubular dilation and vacuolation, interstitial expansion (edema orFrontiers in Immunology | www.frontiersin.org 3fibrosis), inflammatory cell infiltration, protein or cell casts in
tubular lumina was semi-quantitatively evaluated using 0–4 scales:
<5% score 0; 5–25% score 1; 25–50% score 2; 50–75% score 3; and
exceeding 75% score 4. Approximately 12 cortical fields of each
section at 200× magnification were scored by two examiners
blinded to experimental groups (19, 22, 27).
Tubulointerstitial fibrosis was evaluated by Masson’s




FIGURE 1 | Schematic picture of in vivo study design and urinary albumin/creatinine. (A) Bilateral renal pedicles were clamped for 30 min followed by reperfusion for
2 and 8 weeks. Approximately 35 mg/kg CsA gavage daily, and/or 24 nmol/kg CHBP intraperitoneal injection every 3 days. Urine samples were collected every 2
weeks, blood samples were drawn and animals were sacrificed at 2 and 8 weeks. (B–E) The ratio of urinary albumin/creatinine was shown in the IR group with/
without CsA treatment at 2, 4, 6 and 8 weeks. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. (F) The dynamic profile of urinary albumin/creatinine at all-time
points. †P < 0.05, ††P ≤ 0.01, ††††P ≤ 0.0001 versus IR; #P < 0.05, ###P ≤ 0.0005 versus IR + CsA and $P < 0.05 versus the control. Data were expressed as
the mean ± SD of each group (n ≥ 3).July 2021 | Volume 12 | Article 697751
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Image-Pro Plus software (Media Cybernetics, Rockville, USA).
Detection of Apoptotic Cells
Fragmented DNAs in paraffin sections were in situ end labeled
(ISEL) using an ApopTag peroxidase kit (S7100, Appligene
Oncor, Illkirch, France) and 3’-amino-9-ethylcarbazole (SK-
4200, AEC, Vector, Burlingame, USA) as substrate. Apoptotic
cells were counted in tubular, tubular luminal and interstitial
areas in 20 fields at 400× magnification (19, 22).
TCMK-1 cells were tripsinized, re-suspended in binding
buffer and incubated with FITC-conjugated annexin-V and
propidium iodide (PI) for 15 min. Approximately 10,000 cells
were analyzed by BD FACS Calibur flow cytometry (BD
Biosciences, Franklin Lakes, USA). Living cells (Annexin-V
−/PI−), early apoptosis (Annexin-V+/PI−), later apoptosis
(Annexin-V+/PI+) or necrosis (Annexin-V−/PI+) were shown
as quadrant dot plots and the percentage of the gated cells
(18, 26).
Immunohistochemistry
Immunohistochemistry staining of F4/80, a marker of
macrophages, was performed on 4 µm paraffin sections treated
by 40 µg/ml proteinase K (Sigma, Dorset, UK) at 37°C, 30 min
for antigen retrieving. F4/80 (1:50, ab11101, Abcam, Cambridge,
UK) was incubated at 4°C overnight. DAKO EnVision™ + Dual
Link System-HRP was used as the secondary antibody (DAKO,
Glostrup, Denmark). The antibody binding was revealed by 3,3’-
diaminobenzidine (SK-4100, DAB, Vector, Burlingame, USA)
with hematoxylin counterstaining. The number of macrophages
in the tubular, interstitial, and tubular lumen areas were semi-
quantitatively analysed in 20 fields at 400× magnification.
Western Blotting Analysis
Kidney proteins (25 µg) were separated by electrophoresis using
12–15% polyacrylamide gels and blotted onto 0.4 mm
polyvinylidene difluoride membranes (Roche Diagnostics
GmbH, Mannheim, Germany). Membranes were blocked with
5% milk before incubated with full-length CASP-3 (1:200, sc-
7148, Santa Cruz Biochemicals, Santa Cruz, USA), HMGB1
(1:1,000, #3935, Cell Signaling Technology, Beverly, USA) or
b-actin antibody (1:1,000, ab6276, Abcam, Cambridge, UK).
After incubation with peroxidase-conjugated secondary
antibody, the binding was revealed by ECL substrate using a
Molecular Imager Chemi Doc XRS+ system and semi-
quantitatively analyzed by Image Lab Software (Bio-Rad,
Berkeley, USA). Optical volume density values of target
proteins were expressed as the percentage of average controls
after loading correction by b-actin (19, 22).
RT-qPCR
The level of CASP-3 mRNA in kidneys and TCMK-1 cells was
detected by reverse transcription (RT) quantitative real-time
polymerase chain reaction (qPCR) using a StepOne Plus Real-
Time PCR system (Applied Biosystems, Foster City, USA).
Approximately 1 mg of total extracted RNAs was used for RT
of complementary DNA (cDNA). cDNA was amplified in qPCRFrontiers in Immunology | www.frontiersin.org 4reaction buffers (15, 18, 21, 22). The probes of CASP-3 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were 6-
carboxy-fluorescein (FAM) labeled (Thermo Fisher Scientific).
The reaction conditions were as follows: 2 min at 95°C, 40 cycles
of 95°C for 10s, then 60°C for 10s. CASP-3 mRNA normalized by
GAPDH was calculated against control kidneys using a
2−DDCt method.
Antibody Array Analysis
Eighteen well-characterized phosphorylated or cleaved signaling
molecules were simultaneously detected using 50 µg kidney
proteins by a slide-based PathScan® Intracellular Signaling Array
Kit (#7323, Cell Signaling Technology) according to the
manufacturer’s instructions. Images were acquired by briefly
exposing the slide to the Chemi Doc XRS+ system (Bio-Rad), and
semi-quantitatively analyzed by scanning volume density using
Alpha View Software 3.3 (Cell Biosciences, Santa Clara, USA) (33).
Statistical Analysis
Data were represented as the mean ± standard deviation (SD).
One-way analysis of variance (ANOVA) was used to compare
more than two groups, while two-tailed Student’s t-test was used
for two groups using GraphPad Prism 6.0 (GraphPad Software, San
Diego, USA). P ≤0.05 was considered to be statistically significant.RESULTS
CHBP Reduced Urinary Albumin/
Creatinine
The ratio of urinary albumin to creatinine (mg/µmol) was
increased by CsA compared with that produced by IR kidneys
at 4 weeks (Figures 1B, C), while this ratio was also increased by
IR compared with the sham controls at 6 and 8 weeks
(Figures 1D, E). Most impressively, CHBP significantly
decreased urinary albumin/creatinine produced by IR kidneys
with/without CsA treatment at all-time points (Figures 1B–E).
The dynamic profile of urinary albumin/creatinine was higher
in the IR group compared with the control and CHBP treated
groups, and further increased by CsA at all-time points over 2–8
weeks (Figure 1F). The difference between the control and IR
groups was enlarged by prolonged time, and minimized by
CHBP treatment with/without CsA. The change trends in two
CsA groups were surprisingly similar, peaked at 4 weeks,
decreased at 6 weeks and leveled up to 8 weeks.
Nevertheless, there was no significant difference in the level of
SCr between all groups at 2 and 8 weeks (Supplementary
Figures 1A, B).
CHBP Improved Tissue Damage
The semi-quantitative score of TID in H&E sections was
significantly increased by IR compared with the control at both
time points (Figures 2A–D), further increased by CsA with
statistical significance at 8 weeks. Most interestingly, TID was
improved by CHBP in IR kidneys at 2 weeks only, and in the
CsA-treated kidneys at 2 and 8 weeks.July 2021 | Volume 12 | Article 697751
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sections was significantly increased by IR compared with the
control, but improved by CHBP at both time points
(Figures 3A–D), while CsA increased interstitial fibrosis was
significantly decreased by CHBP at 8 weeks only.
Cellular Apoptosis in Kidneys Reduced by
CHBP and CsA
Apoptotic cells detected by ISEL were mainly located in the
tubular and interstitial areas (Figures 4A–J), some of them had
polymorphic nuclei (4B1, C1), with very few seen in glomerular
areas. The total number of apoptotic cells, summed up from that
in tubular and interstitial areas and tubular lumina, was greatlyFrontiers in Immunology | www.frontiersin.org 5increased by IR, but decreased by CsA at 2 and 8 weeks, and by
CHBP at 8 weeks (Figures 4K, L).
Macrophages in Kidneys Affected by
CHBP and CsA
F4/80+ macrophages were mainly located in the interstitial
areas (Supplementary Figure 2A) . The number of
macrophages in interstitial areas increased by IR was
numerically decreased by CsA and CHBP at 2 weeks, but did
not reach statistical significance (Supplementary Figure 2B).
In addition, the increase trend induced by CsA was also seen at






FIGURE 2 | The semi-quantitative score of TID in H&E staining sections. (A, C) Tubular dilation, epithelial cell vacuolation, interstitial expansion with edema or
inflammation, and cells or cell debris in tubular lumens were mainly seen in IR kidneys. (B) CHBP treatment improved the TID compared with IR and IR + CsA
groups at 2 weeks. (D) The score was further increased in the IR + CsA group but reversed by CHBP at 8 weeks. Data were expressed as the mean ± SD of
each group (n ≥ 3). *P ≤ 0.05; **P ≤ 0.01.July 2021 | Volume 12 | Article 697751
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Reduced by CHBP
CASP-3 mRNA measured by qPCR was increased by IR at both
time points, and further increased by CsA at 2 weeks, but decreased
by CHBP in the CsA group at 8 weeks (Figures 5A, E).
CASP-3 protein was detected by western blotting,
(Figures 5B, C, F). Approximately 17 kD active CASP-3 was
increased by IR and reversed by CHBP at 2 weeks; further
increased by CsA at 8 weeks was also reversed by CHBP
(Figures 5D, G).
HMGB1 Protein Decreased by CHBP
CHBP decreased the increased HMGB1 protein by IR at 2 weeks
(Figures 5H, I) and the further increased HMGB1 by CsA
compared with IR kidneys at 8 weeks (Figures 5H, J), detected
by western blotting.Frontiers in Immunology | www.frontiersin.org 6Different Proteins Changed at 2 and
8 Weeks
Eighteen proteins in the kidney were detected at the same time by
slide-based antibody array (Figures 6A, B). In IR kidneys with/
without CHBP treatment, CsA decreased p70 S6 kinase, mTOR
and CASP-3 at 2 weeks, and GSK-3b and CASP-3 at 8 weeks
(Figures 6C–E, G, H). However, S6 ribosomal protein (S6RP)
was decreased by CsA in IR kidneys, but reversed by CHBP
(Figure 6F). CASP-3 was decreased by CHBP in CsA treated IR
kidneys at 2 weeks and in IR kidneys at 8 weeks (Figures 6E–H).
CHBP Reduced CASP-3 and Apoptosis
Increased by CsA in TCMK-1 Cells
CASP-3 mRNA was gradually increased by 2.5–20 mg/ml CsA
(Figure 7B), so was early apoptotic cells, and reached statistical




FIGURE 3 | The score of interstitial fibrosis in Masson’s trichrome stained sections. (A, C) Masson’s trichrome staining revealed the interstitial fibrosis.
(B, D) Interstitial fibrosis was increased by IR compared with the control, but improved by CHBP at both time points. (D) The score of fibrosis was significantly
decreased by CHBP in the CsA treated group at 8 weeks. Data were expressed as the mean ± SD of each group (n ≥ 3). **P ≤ 0.01.July 2021 | Volume 12 | Article 697751
Zhang et al. Renoprotection and Mechanism of CHBPFIGURE 4 | Apoptotic cells detected by labelling fragmented DNAs. (A–J) Apoptosis were mainly shown in tubular and interstitial areas. (B1–D1, G1–I1) Enlarged
pictures were from (B–D) and (G–I). (K, L) The number of apoptotic cells was greatly increased by IR, but decreased by CsA at 2 and 8 weeks. CHBP treatment
decreased apoptotic cells in the IR kidneys at 8 weeks. Data were expressed as the mean ± SD of each group (n ≥ 3). *P ≤ 0.05; **P ≤ 0.01.Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 6977517
Zhang et al. Renoprotection and Mechanism of CHBPapoptotic cells were gradually reduced by 2.5–40 ng/ml CHBP, and
reached statistical significance at 20–40 ng/ml (Figures 7D, E).
CASP-3siRNA Decreased CASP-3 mRNA
and Apoptosis in TCMK-1 Cells
CASP-3 mRNA was reduced by 10–30 nM/ml CASP-3siRNA
compared with the control treated by 20 mg/ml CsA or withFrontiers in Immunology | www.frontiersin.org 8NCsiRNA. The suppression was maximized by CASP-3siRNA at
30nM/mlwith64.85%reduction (Figure7F).CASP-3mRNAwere
significantly increased by 20 mg/ml CsA, but reversed by 20 ng/ml
CHBP with/without 30 nM CASP-3siRNA (Figure 7G).
Early apoptotic cells was also significantly increased by 20 mg/ml
CsA, but reversed by CHBP with/without CASP-3siRNA or




FIGURE 5 | CASP-3 mRNA and protein, and HMGB1 protein expression. (A, E) The relative expression of caspase 3 mRNA was increased by IR at both time
points, and further increased by CsA at 2 weeks, but decreased by CHBP in the CsA group at 8 weeks. (B–D, F, G) The level of 17 kD active CASP-3 protein was
increased by IR and reversed by CHBP at 2 weeks, and increased by CsA at 8 weeks and also reversed by CHBP. (H–J) The expression of HMGB1 protein in 2
and 8 weeks was detected by western blotting. The level of HMGB1 was significantly decreased by CHBP in the IR group at 2 weeks, increased by CsA compared
with the IR group and reversed by CHBP at 8 weeks. Data were expressed as the mean ± SD (n ≥ 3). The volume density of western blots was corrected by against
42 kD b-actin as a loading control. *P ≤ 0.05; **P ≤ 0.01.July 2021 | Volume 12 | Article 697751
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FIGURE 6 | Simultaneous detection of 18 proteins by slide-based antibody array. (A, B) The expression of 18 proteins in the kidneys revealed by slide-based
antibody array. (C–E) CsA decreased p70 S6 kinase, mTOR and caspase-3 at 2 weeks. (F–H) S6RP was decreased by CsA in IR kidneys, but reversed by CHBP.
CsA decreased GSK-3b and caspase-3 at 8 weeks in IR kidneys with/without CHBP treatment. (E–H) Caspase-3 was decreased by CHBP in CsA treated IR
kidneys at 2 weeks and in IR kidneys at 8 weeks. Data were expressed as the mean ± SD (n ≥ 3). The volume density was corrected by against the control.
*P ≤ 0.05; **P ≤ 0.01.Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 6977519






FIGURE 7 | Schematic picture of in vitro study design and effects of CsA, CHBP and CASP-3siRNA on TCMK-1 cells. (A) TCMK-1 cells were transfected with
CASP-3siRNA 4–6 h before treated by CsA with/without CHBP for 24 h. (B) The level of CASP-3 mRNA was gradually increased by 2.5–20 mg/ml CsA. (C) The
percentage of early apoptotic cells was significantly increased by CsA by 20–40 mg/ml and peaked at 20 mg/ml. (D, E) Early apoptotic cells was gradually reduced
by 2.5–40 ng/ml CHBP, and reached statistical significance at 20–40 ng/ml. (F) The expression of CASP-3 mRNA was reduced by 10–30 nM/ml CASP-3siRNA
compared with the control treated by 20 mg/ml CsA or with NCsiRNA, but the suppression was maximized at 30 nM/ml with 64.85% reduction. (G) CASP-3 mRNA
were significantly increased by 20 mg/ml CsA, but reversed by 20 ng/ml CHBP with/without 30 nM CASP-3siRNA. (H, I) Early apoptotic cells was significantly
increased by 20 mg/ml CsA, but reversed by CHBP with/without CASP-3siRNA or NCsiRNA. Data were expressed as the mean ± SD, (n = 3). *P < 0.05, **P < 0.01.Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 69775110
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apoptotic cells compared with the CsA + CHBP +NCsiRNA group.DISCUSSION
The renoprotection of CHBP against IR injury and HBSP against
IR and CsA-induced injury has been shown previously (18, 20,
26, 27). However, there has been no report regarding the long-
term effect of CHBP on IR and CsA-induced combinational
injury in mouse models. In this study, the renoprotection of
CHBP was confirmed not only in renal IR injury but also with
CsA nephrotoxicity at 2 and 8 weeks, which better mimicked
human kidney transplantation. Urinary albumin/creatinine was
more sensitive than SCr in detecting transplant-related injuries,
which was supported by changes in apoptosis, inflammation,
TID and tubulointerstitial fibrosis. The renoprotective
mechanisms of CHBP on IR injury and CsA nephrotoxicity
might be different, with decreased mTOR and p70 S6 kinase at 2
weeks, GSK-3b and S6RP at 8 weeks, and CASP-3 protein at both
time points. These changes may reflect the dynamic nature of
two different injuries, in terms of IR injury gradually eased off in
2 weeks, but CsA nephrotoxicity continuously built up over 8
weeks. In addition, the effect of CsA on apoptosis appeared
differently in kidneys having different cell types and kidney
epithelial cells in vitro (Supplementary Figure 3).
CsA is widely used in organ transplantation to prevent
rejection, but its nephrotoxicity cannot be ignored (34, 35).
Previous long-term studies of kidney IR injury revealed that
CsA increased interstitial inflammation and renal fibrosis (19,
21). To explore the pathogenesis of CAD in-depth, the mouse
model subjected to renal transplant-related injuries, IR injury
and CsA nephrotoxity, was established at 2 and 8 weeks. Urinary
albumin/creatinine was increased by IR injury, together with
TID, interstitial fibrosis and apoptotic cells in tubular areas. CsA
further increased urinary albumin/creatinine from 2 and 4
weeks. However, SCr was not statistically different between
groups. Urinary albumin/creatinine, therefore, is a non-
invasive and more sensitive biomarker than SCr in monitoring
renal transplant-related injuries for middle/long-term.
CsA reduced apoptotic cells in IR kidneys at both time points,
which was contradictory to the change in TID, CASP-3,
HMGB1, tubulointerstitial fibrosis, and CsA-induced early
apoptosis in TCMK-1 cells. Apoptosis is an inevitable
phenomenon in transplant-related kidney damage (36), while
the apoptosis in different types of cells could lead to inverse
outcomes: on one hand excessive TEC apoptosis resulting in
tubular atrophy and dysfunction; on the other hand,
inflammatory cell apoptosis facilitating the clearance of
inflammation, renal structure remodeling and functional
recovery (37, 38). Furthermore, the number of macrophages
was detected to evaluate the effect of CHBP/CsA on infiltrated
inflammatory cells. The results showed that IR increased
macrophages mainly located in the interstitial areas were
numerously decreased by CsA and further decreased by CHBP
at 2 weeks, both of which were reversed at 8 weeks. Because of theFrontiers in Immunology | www.frontiersin.org 11large variation between individual animals, there was no any
statistically significant difference between groups. Therefore, we
concluded that CsA might help renal structure remodeling and
functional recovery by decreased apoptosis of TECs at 2 weeks.
However, the intensive inflammation at 8 weeks, with decreased
apoptosis of inflammatory cells, might aggravate the structural
damage of kidneys, impede functional recovery, and lead to
tubulointerstitial fibrosis that characterizes CsA-induced long-
term nephrotoxicity (21).
The renoprotection of CHBP against IR injury and/or CsA
nephrotoxicity was also demonstrated. Given that urinary
albumin/creatinine was decreased by CHBP in IR injury and/
or CsA groups from 2, 4, 6 to 8 weeks, and TID, active CASP-3
and HMGB1 expression and fibrosis were improved by CHBP in
IR kidneys at 2 weeks. IR-induced apoptotic cells were decreased
by CHBP at 8 weeks only, which implies the nature of the model
in terms of the apoptosis in different types of cells. In addition,
CHBP improved interstitial fibrosis, decreased CASP-3 mRNA
and 17 kD protein, and HMGB1 in IR kidneys with additional
CsA only at 8 weeks, which suggests that the accumulated
nephrotoxic ity of CsA might further faci l i tate the
renoprotection of CHBP. Therefore, the renoprotection of
CHBP was embodied in either improving IR injury, TID and
inflammation at 2 weeks, or reducing accumulated CsA
nephrotoxicity, apoptosis and interstitial fibrosis at 8 weeks.
To further investigate whether CHBP has comparable
immune regulating responses with CsA or what different
underlying mechanisms involved in IR injury with/without
CsA at 2 and 8 weeks, the expression of multiple mechanistic
signaling proteins was analyzed in the same sample by a slide
based antibody array. p70 S6 kinase, mTOR, and CASP-3 were
decreased by CsA in IR kidneys at 2 weeks, while S6RP, GSK-3b
and CASP-3 were reduced at 8 weeks. CHBP also downregulated
CASP-3 in IR + CsA treated kidneys at 2 weeks and in IR kidneys
at 8 weeks, but upregulated S6RP at 8 weeks in IR kidneys with
CsA treatment. It suggests that CHBP protecting IR injury and/
or CsA nephrotoxicity might be associated with different
mechanistic signaling pathways, with CASP-3 at convergent
point. Therefore, CASP3siRNA therapy might be an additional
treatment to CHBP for transplant-related renal injury.
Our previous studies have shown the up-regulated CASP-3 in
TECs associated with apoptosis and inflammation in different
IR-induced acute and chronic kidney injuries (3, 18, 19, 21, 39),
and the renoprotection of CASP-3siRNA (22, 40, 41). In order to
dissect the effect and mechanism of CHBP and CsA, TCMK-1
cells were stimulated by CsA, and also treated with CHBP and/or
CASP-3siRNA. Approximately 20 mg/ml CsA and 20 ng/ml
CHBP were most effective at 24 h. CASP-3 mRNA and early
apoptotic cells were dose-dependently increased by CsA, but
reversed by CHBP with or without CASP-3siRNA, while early
apoptotic cells were further decreased by CHBP together with
CASP-3siRNA. These results reveal that CHBP combined with
CASP-3siRNA had a profound protection against CsA-induced
TEC injury by anti-apoptosis. The synergistic effect of both was
also revealed in mouse IR kidneys at 48 h in one of our more
recent studies (42).July 2021 | Volume 12 | Article 697751
Zhang et al. Renoprotection and Mechanism of CHBPThis finding needs to be further validated in animal models at
the suitable stage of injury using modified CASP-3siRNA via
optimized delivery route. The results from this study guide our
near future investigations: whether CHBP has comparable
immune regulating function with CsA; how different is the
underlying mechanism of IR injury and/or CsA nephrotoxity
at 2 and 8 weeks; how to combine CHBP with siRNA for
therapeutic applications at different stages of injury. The
precise mechanism of CHBP and combined effect with CASP-
3siRNA are worth further investigating.
In conclusion, the predominant renoprotection of CHBP against
IR injury was at 2 weeks, and against CsA nephrotoxicity was at 8
weeks, with urinary albumin/creatinine as a good biomarker in
monitoring the progression of transplant-related chronic injuries.
The renoprotection of CHBP was associated with different
mechanistic signaling proteins such as mTOR at 2 weeks and
GSK-3b at 8 weeks, and CASP-3 at both time points. CHBP
combined with CASP-3siRNA had a profound protection against
CsA-induced injury in TECs, although CsA divergently affected
apoptosis in kidneys and TECs.DATA AVAILABILITY STATEMENT
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